NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Tronox Holdings plc (NYSE: TROX) between February 12, 2025 and July 30, 2025, both dates inclusive (the “Class Period”), of the important November 3, 2025 lead plaintiff deadline. SO WHAT: If you purchased Tronox common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangemen ...

NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 and September 12, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. SO WHAT: If you purchased aTyr Pharma common stock du ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of American Depositary Shares (ADS) of WPP plc, covering the period from February 27, 2025, to July 8, 2025, due to allegations of misleading statements regarding the company's media arm and its market position [1][5]. Group 1: Lawsuit Details - The class action lawsuit allows investors who purchased WPP plc ADSs during the specified period to seek compensation without incurring out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must be appointed by December 8, 2025, to represent the class in the litigation [1][3]. - The complaint alleges that WPP provided overly positive statements while concealing material adverse facts about its media arm's ability to handle macroeconomic challenges and its loss of market share [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - The founding partner, Laurence Rosen, has been recognized as a Titan of Plaintiffs' Bar by Law360 [4].

SO WHAT: If you purchased Cytokinetics common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the "Class Period"), of the important November 17, 2025 lead plaintiff deadline. WHAT TO DO NEXT: To join the Cyt ...

Core Points - Rosen Law Firm is reminding purchasers of Snap Inc. securities from April 29, 2025, to August 5, 2025, about the October 20, 2025, lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Snap securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by October 20, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. Group 2: Case Background - The lawsuit alleges that Snap's defendants misrepresented the company's advertising revenue and growth potential while downplaying macroeconomic instability [5]. - It is claimed that Snap's optimistic reports did not reflect the reality of its execution errors, leading to investor damages when the truth was revealed [5].

NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fluor Corporation (NYSE: FLR) between February 18, 2025 and July 31, 2025, both dates inclusive (the “Class Period”), of the important November 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Fluor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT ...

NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of V.F. Corporation (NYSE: VFC) between October 30, 2023 and May 20, 2025, both dates inclusive (the “Class Period”), of the important November 12, 2025 lead plaintiff deadline. SO WHAT: If you purchased V.F. Corporation securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangeme ...

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Quantum Corporation (NASDAQ: QMCO) between November 15, 2024 and August 18, 2025, inclusive (the “Class Period”), of the important November 3, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Quantum Corporation securities during the Class Period you may be entitled to compensation without payment of any out of ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Jasper Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and compliance with cGMP regulations, which could negatively impact the clinical and commercial prospects of its products, including briquilimab [5]. - The failure to disclose these issues increased the risk of confounding study results and the likelihood of disruptive cost-reduction measures, leading to an overstatement of Jasper's business and financial prospects [5].

NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fly-E Group, Inc. (NASDAQ: FLYE) between July 15, 2025 and August 14, 2025, both dates inclusive (the “Class Period”), of the important November 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Fly-E securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHA ...